Evoke Wealth LLC Boosts Stock Position in Boston Scientific Co. (NYSE:BSX)

Evoke Wealth LLC raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 26.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 3,541 shares of the medical equipment provider’s stock after acquiring an additional 738 shares during the period. Evoke Wealth LLC’s holdings in Boston Scientific were worth $316,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Horizon Investments LLC raised its stake in Boston Scientific by 1.4% during the 4th quarter. Horizon Investments LLC now owns 22,140 shares of the medical equipment provider’s stock valued at $1,978,000 after acquiring an additional 295 shares during the last quarter. Advisors Asset Management Inc. increased its position in Boston Scientific by 41.2% during the 4th quarter. Advisors Asset Management Inc. now owns 33,970 shares of the medical equipment provider’s stock worth $3,034,000 after purchasing an additional 9,910 shares during the period. Thrivent Financial for Lutherans increased its position in Boston Scientific by 49.8% during the 4th quarter. Thrivent Financial for Lutherans now owns 549,364 shares of the medical equipment provider’s stock worth $49,030,000 after purchasing an additional 182,557 shares during the period. PDS Planning Inc increased its position in Boston Scientific by 1.5% during the 4th quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider’s stock worth $668,000 after purchasing an additional 113 shares during the period. Finally, Signaturefd LLC increased its position in Boston Scientific by 4.9% during the 4th quarter. Signaturefd LLC now owns 29,237 shares of the medical equipment provider’s stock worth $2,611,000 after purchasing an additional 1,368 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Trading Up 1.6 %

Shares of BSX opened at $100.77 on Thursday. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $148.72 billion, a P/E ratio of 80.62, a price-to-earnings-growth ratio of 2.79 and a beta of 0.77. The stock’s fifty day simple moving average is $101.45 and its 200 day simple moving average is $92.15. Boston Scientific Co. has a twelve month low of $66.80 and a twelve month high of $107.17.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, equities research analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Analyst Ratings Changes

BSX has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Deutsche Bank Aktiengesellschaft upgraded Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a research report on Friday, January 10th. Royal Bank of Canada boosted their target price on Boston Scientific from $105.00 to $116.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. UBS Group upped their price target on Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Friday, February 7th. Finally, Truist Financial upped their price target on Boston Scientific from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average price target of $108.91.

Insider Buying and Selling

In related news, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the completion of the sale, the executive vice president now directly owns 35,319 shares in the company, valued at approximately $3,179,416.38. This represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the sale, the executive vice president now owns 28,454 shares of the company’s stock, valued at approximately $2,966,329.50. This represents a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 137,302 shares of company stock valued at $14,319,269. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.